华森制药(002907) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥154.80 million, a decrease of 20.23% compared to the same period last year, and year-to-date revenue was ¥515.26 million, down 8.27% year-on-year[5]. - Net profit attributable to shareholders for Q3 2023 was ¥3.41 million, a decline of 83.65%, while year-to-date net profit was ¥44.78 million, down 38.54%[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥1.57 million, a decrease of 91.46%, with year-to-date figures at ¥37.39 million, down 37.86%[5]. - Total operating revenue for the third quarter of 2023 was CNY 515,257,554.58, a decrease of 8.25% compared to CNY 561,689,616.37 in the same period last year[22]. - Net profit for the third quarter was CNY 44,775,006.77, down 38.5% from CNY 72,847,006.41 in the previous year[23]. - Basic and diluted earnings per share for the third quarter were CNY 0.1072, down from CNY 0.1816 in the same period last year[24]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥180.28 million, an increase of 132.41%[5]. - The net cash flow from operating activities increased by 132.41% to ¥180,280,978.10 compared to ¥77,571,456.00 in the same period last year, primarily due to the release of restricted funds from the previous period[15]. - Cash inflows from operating activities totaled ¥673,672,715.71, compared to ¥513,646,935.93 in the previous period, indicating a growth of about 31.2%[25]. - The cash outflows from operating activities were ¥493,391,737.61, up from ¥436,075,479.93, reflecting an increase of approximately 13.2%[25]. - The net cash flow from investing activities decreased by 84.11% to -¥102,442,725.25, influenced by increased expenditures on property purchases and reduced external investments[15]. - The net cash flow from investing activities was -¥102,442,725.25, worsening from -¥55,641,234.56 in the previous period[26]. - Cash inflows from financing activities amounted to ¥70,200,000.00, with cash outflows totaling ¥100,374,959.01, resulting in a net cash flow of -¥30,174,959.01[26]. - The ending balance of cash and cash equivalents increased to ¥453,534,336.74 from ¥422,039,676.26, marking a rise of approximately 7.4%[26]. - The company reported a significant increase in cash received from other operating activities, totaling ¥125,045,703.50, compared to ¥21,975,422.91 previously, an increase of approximately 468.5%[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1.85 billion, a decrease of 1.12% from the end of the previous year[5]. - The company's total assets as of September 30, 2023, were CNY 1,845,694,344.08, slightly down from CNY 1,866,666,731.37 at the beginning of the year[21]. - Non-current liabilities decreased to CNY 46,069,101.74 from CNY 44,957,035.03, indicating a slight increase of 2.5%[21]. - The company's long-term equity investments decreased slightly to ¥24,682,946.61 from ¥25,975,029.50 at the beginning of the year[19]. Research and Development - The company increased its R&D investment by 12.53% year-on-year, with R&D expenses rising by 26.98% compared to the previous year[6]. - Research and development expenses increased to CNY 49,402,354.90, up from CNY 38,905,107.64, representing a growth of 27.5%[22]. - The company anticipates that its ongoing R&D efforts and new product launches will contribute to future revenue growth and create new performance growth points[7]. Inventory and Receivables - The company reported a 42.30% increase in inventory, amounting to ¥163.30 million, primarily due to increased raw material and product stock[12]. - The company experienced a significant decrease in accounts receivable by 40.35%, totaling ¥58.57 million, due to reduced new bills and settlements[12]. Other Income and Expenses - Other income fell by 33.12% to ¥8,652,056.35, mainly due to a reduction in government subsidies received during the current period[14]. - Investment income decreased by 65.05% to -¥5,339,465.57, primarily due to no purchase of financial products and joint ventures not yet generating profits[14]. - Financial expenses decreased by 195.69% to -¥6,376,091.19, attributed to the redemption of convertible bonds, resulting in no financial expense amortization for the current period[14]. - The company reported a credit impairment loss of CNY 1,645,786.78, compared to a loss of CNY -3,141,569.14 in the previous year, indicating a significant improvement in credit quality[23]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,021, with the top ten shareholders holding significant stakes, including Chengdu Local Construction Machinery Engineering Co., Ltd. at 45.04%[17]. Audit Status - The company has not undergone an audit for the third-quarter report[27].